Skip to main content

Advertisement

SpringerLink
Log in

Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines?

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate the impact of androgen ablation therapy in different prostate cancer (PCa) cell lines—reflecting different stages of the disease—on 18F-fluorodeoxyglucose (FDG), 11C-choline and 11C-acetate uptake.

Methods

Uptake experiments were performed in androgen-sensitive (LNCaP, PC346C) and independent cell lines (22Rv1, PC346DCC, PC-3) as well as in a benign prostatic hyperplasia (BPH-1) cell line. Tracer uptake was assessed under androgen ablation. Results of the cancer cell lines were normalized to those of BPH-1. To evaluate the effect of androgen on the uptake of 18F-FDG, 11C-choline and 11C-acetate in PCa cell lines, 10−8M R1881, 10−10M R1881, the combination of 10−10M R1881 plus 10−6M Casodex or 10−6M Casodex alone were added in parallel cell cultures 1 day before uptake experiments. Uptake in androgen-supplemented cell cultures was compared to the uptake under androgen deprivation. Uptake was corrected for cell number using protein content.

Results

Compared to BPH-1, a higher 18F-FDG uptake was observed only in PC346C cells, whereas a higher 11C-choline and markedly increased 11C-acetate uptake was seen in all cancer cell lines. Androgens significantly modulated the uptake of 18F-FDG in LNCaP, PC346C and 22Rv1 cells, and of 11C-choline in the PC346C and 22Rv1 cell line. No androgenic effect on 11C-choline and 18F-FDG uptake was observed in PC-3 and PC346DCC cells. 11C-Acetate uptake was independent of androgen status in all PCa cell lines studied.

Conclusion

18F-FDG uptake in PCa cell lines showed the highest variability and strongest androgen effect, suggesting its poor potential for metabolic imaging of advanced PCa. In contrast to 18F-FDG and 11C-choline, 11C-acetate uptake was unaffected by androgens and thus 11C-acetate seems best for monitoring PCa progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Schöder H, Herrmann K, Gönen M, Hricak H, Eberhard S, Scardino P, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005;11:4761–9.

    Article  PubMed  Google Scholar 

  3. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108–11.

    Article  PubMed  CAS  Google Scholar 

  4. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31–5.

    Article  PubMed  CAS  Google Scholar 

  5. Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30:607–11.

    Article  PubMed  CAS  Google Scholar 

  6. Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005;11:3210–6.

    Article  PubMed  CAS  Google Scholar 

  7. Oyama N, Akino H, Suzuki Y, Kanamaru H, Miwa Y, Tsuka H, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002;4:99–104.

    Article  PubMed  Google Scholar 

  8. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317–24.

    Article  PubMed  CAS  Google Scholar 

  9. Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, et al. Radiation dose estimates in humans for (11)C-acetate whole-body PET. J Nucl Med 2004;45:1233–6.

    PubMed  CAS  Google Scholar 

  10. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990–5.

    PubMed  CAS  Google Scholar 

  11. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249–54.

    PubMed  CAS  Google Scholar 

  12. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181–6.

    PubMed  CAS  Google Scholar 

  13. Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549–55.

    PubMed  CAS  Google Scholar 

  14. Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003;42:25–30.

    PubMed  CAS  Google Scholar 

  15. Swinnen JV, Verhoeven G. Androgens and the control of lipid metabolism in human prostate cancer cells. J Steroid Biochem Mol Biol 1998;65:191–8.

    Article  PubMed  CAS  Google Scholar 

  16. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34–45.

    Article  PubMed  CAS  Google Scholar 

  17. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001;22:963–9.

    Article  PubMed  CAS  Google Scholar 

  18. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1065–73.

    Article  PubMed  CAS  Google Scholar 

  19. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31:14–24.

    Article  PubMed  CAS  Google Scholar 

  20. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809–18.

    PubMed  CAS  Google Scholar 

  21. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, et al. Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment. Int J Cancer 2005;117:221–9.

    Article  PubMed  CAS  Google Scholar 

  22. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403–9.

    Article  PubMed  CAS  Google Scholar 

  23. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606–14.

    PubMed  CAS  Google Scholar 

  24. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205–25.

    Article  PubMed  Google Scholar 

  25. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16–23.

    PubMed  CAS  Google Scholar 

  26. Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006;33:977–84.

    Article  PubMed  CAS  Google Scholar 

  27. Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res 2004;24:3057–63.

    PubMed  CAS  Google Scholar 

  28. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625–32.

    PubMed  CAS  Google Scholar 

  29. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9:2416–25.

    PubMed  CAS  Google Scholar 

  30. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y, et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 2007;5:383–91.

    Article  PubMed  CAS  Google Scholar 

  31. Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ, Kim JW, et al. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 2010;433:225–33.

    Article  Google Scholar 

  32. Müller SA, Holzapfel K, Seidl C, Treiber U, Krause BJ, Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging 2009;36:1434–42.

    Article  PubMed  Google Scholar 

  33. Al-Saeedi F, Welch AE, Smith TA. [methyl-3H]Choline incorporation into MCF7 tumour cells: correlation with proliferation. Eur J Nucl Med Mol Imaging 2005;32:660–7.

    Article  PubMed  CAS  Google Scholar 

  34. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32:668–73.

    Article  PubMed  Google Scholar 

  35. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599–603.

    PubMed  CAS  Google Scholar 

  36. Jadvar H, Gurbuz A, Li X, Shahinian A, Conti PS. Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging 2008;7:147–52.

    PubMed  Google Scholar 

  37. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:301–9.

    Article  PubMed  Google Scholar 

  38. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999;343(Pt 2):281–99.

    Article  PubMed  CAS  Google Scholar 

  39. Oyama N, Kim J, Jones LA, Mercer NM, Engelbach JA, Sharp TL, et al. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol 2002;29:783–90.

    Article  PubMed  CAS  Google Scholar 

  40. Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011;36:192–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Prof. Dr. Karin Haustermans and MSc. Sofie Isebaert. This study was supported by the Molecular Small Animal Imaging Center (MoSAIC) of the K.U.Leuven, Belgium and the Interuniversity Attraction Poles grant (IUAP6/38) is kindly acknowledged.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Gasthuisberg Leuven, Leuven, Belgium

    Kimy M. Emonds, Johan Nuyts, Luc Mortelmans & Felix M. Mottaghy

  2. Laboratory for Experimental Medicine and Endocrinology, Department of Experimental Medicine, K.U.Leuven, Leuven, Belgium

    Johannes V. Swinnen & Frank Vanderhoydonc

  3. Department of Experimental Urology, Josephine Nefkens Institute, Erasmus University Rotterdam, Rotterdam, The Netherlands

    Wytske M. van Weerden

  4. Department of Nuclear Medicine, University Hospital Aachen, Pauwelsstr. 30, 52057, Aachen, Germany

    Felix M. Mottaghy

  5. Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

    Felix M. Mottaghy

Authors
  1. Kimy M. Emonds
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes V. Swinnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wytske M. van Weerden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frank Vanderhoydonc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Johan Nuyts
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luc Mortelmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Felix M. Mottaghy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felix M. Mottaghy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Emonds, K.M., Swinnen, J.V., van Weerden, W.M. et al. Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines?. Eur J Nucl Med Mol Imaging 38, 1842–1853 (2011). https://doi.org/10.1007/s00259-011-1861-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-011-1861-6

Keywords

Search

Navigation